Shiv Ram Krishn
Overview
Explore the profile of Shiv Ram Krishn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
716
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boreddy S, Nair R, Pandey P, Kuriakose A, Marigowda S, Dey C, et al.
Cancer Res
. 2023 Apr;
83(11):1883-1904.
PMID: 37074042
Significance: The bifunctional mAb fusion design of BCA101 targets it to the tumor microenvironment where it inhibits EGFR and neutralizes TGFβ to induce immune activation and to suppress tumor growth.
2.
Quaglia F, Krishn S, Sossey-Alaoui K, Rana P, Pluskota E, Park P, et al.
Sci Rep
. 2022 Nov;
12(1):18879.
PMID: 36344556
Androgen deprivation therapies aimed to target prostate cancer (PrCa) are only partially successful given the occurrence of neuroendocrine PrCa (NEPrCa), a highly aggressive and highly metastatic form of PrCa, for...
3.
Krishn S, Garcia V, Naranjo N, Quaglia F, Shields C, Harris M, et al.
Cancer Biol Ther
. 2022 Feb;
23(1):173-185.
PMID: 35188070
The αVβ6 integrin, an epithelial-specific cell surface receptor absent in normal prostate and expressed during prostate cancer (PrCa) progression, is a therapeutic target in many cancers. Here, we report that...
4.
Ganguly K, Bhatia R, Rauth S, Kisling A, Atri P, Thompson C, et al.
Gastroenterology
. 2021 Sep;
162(1):253-268.e13.
PMID: 34534538
Background & Aims: A major clinical challenge for patients with pancreatic cancer (PC) is metabolic adaptation. Neoplastic cells harboring molecular perturbations suffice for their increased anabolic demand and nucleotide biosynthesis...
5.
Quaglia F, Krishn S, Wang Y, Goodrich D, McCue P, Kossenkov A, et al.
PLoS One
. 2021 Jan;
16(1):e0244985.
PMID: 33481853
Neuroendocrine prostate cancer (NEPrCa) arises de novo or after accumulation of genomic alterations in pre-existing adenocarcinoma tumors in response to androgen deprivation therapies. We have provided evidence that small extracellular...
6.
Ganguly K, Krishn S, Rachagani S, Jahan R, Shah A, Nallasamy P, et al.
Cancer Res
. 2020 Oct;
81(1):91-102.
PMID: 33127746
Secreted mucin 5AC (MUC5AC) is the most abundantly overexpressed member of the mucin family during early pancreatic intraepithelial neoplasia stage I (PanIN-I) of pancreatic cancer. To comprehend the contribution of...
7.
Salem I, Naranjo N, Singh A, DeRita R, Krishn S, Sirman L, et al.
Cancer Drug Resist
. 2020 Oct;
3:371-384.
PMID: 33062957
Cells are known to release different types of vesicles such as small extracellular vesicles (sEVs) and large extracellular vesicles (LEVs). sEVs and LEVs play important roles in intercellular communication, pre-metastatic...
8.
Quaglia F, Krishn S, Daaboul G, Sarker S, Pippa R, Domingo-Domenech J, et al.
J Extracell Vesicles
. 2020 Sep;
9(1):1761072.
PMID: 32922691
The ability of small extracellular vesicles (sEVs) to reprogram cancer cells is well established. However, the specific sEV components able to mediate aberrant effects in cancer cells have not been...
9.
Bertolini I, Ghosh J, Kossenkov A, Mulugu S, Krishn S, Vaira V, et al.
Dev Cell
. 2020 Aug;
55(2):163-177.e6.
PMID: 32780991
The crosstalk between tumor cells and the adjacent normal epithelium contributes to cancer progression, but its regulators have remained elusive. Here, we show that breast cancer cells maintained in hypoxia...
10.
Mallya K, Haridas D, Seshacharyulu P, Pothuraju R, Junker W, Krishn S, et al.
Biol Open
. 2020 Jul;
9(9).
PMID: 32709695
Pancreatic cancer (PC) is acquired postnatally; to mimic this scenario, we developed an inducible Kras; Ptf1a-CreER™ (iKC) mouse model, in which Kras is activated postnatally at week 16 upon tamoxifen...